Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RXRX | US
0
0%
Healthcare
Biotechnology
30/06/2024
04/10/2024
6.11
6.15
6.34
6.07
Recursion Pharmaceuticals Inc. operates as a clinical-stage biotechnology company engages in the decoding biology by integrating technological innovations across biology chemistry automation data science and engineering to industrialize drug discovery. The company develops REC-994 which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282 which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881 which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964 which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881 which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1 an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Salt Lake City Utah.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
51.9%1 month
44.7%3 months
74.0%6 months
70.7%-
-
3.37
0.15
0.12
-5.31
32.61
-
-364.95M
1.72B
1.72B
-
-697.39
-
30.90
-71.18
12.37
29.22
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.23
Range1M
1.52
Range3M
2.85
Rel. volume
0.79
Price X volume
23.51M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 39.26 | 1.87B | -5.37% | n/a | 138.24% |
Intellia Therapeutics Inc | NTLA | Biotechnology | 17.99 | 1.83B | -3.02% | n/a | 10.95% |
VIRIDIAN THERAPEUTICS ORS INC | VRDN | Biotechnology | 23.92 | 1.83B | -1.36% | n/a | 3.96% |
MannKind Corporation | MNKD | Biotechnology | 6.49 | 1.78B | 3.18% | 124.00 | -149.80% |
Certara Inc. | CERT | Biotechnology | 11.09 | 1.78B | -2.46% | n/a | 29.96% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 24.48 | 1.74B | -0.20% | n/a | 2.62% |
Arvinas Inc | ARVN | Biotechnology | 24.96 | 1.71B | 1.05% | n/a | 0.38% |
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 23.6 | 1.63B | 4.61% | n/a | 4.89% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.31 | 0.76 | Cheaper |
Ent. to Revenue | 32.61 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.37 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 74.01 | 74.67 | Par |
Debt to Equity | 0.15 | -1.82 | Expensive |
Debt to Assets | 0.12 | 0.26 | Cheaper |
Market Cap | 1.72B | 3.73B | Emerging |